Literature DB >> 203712

Oncornavirus lytic activity in the serum of gibbon apes.

R E Gallagher, A W Schrecker, C A Walter, R C Gallo.   

Abstract

Fresh blood serum from normal gibbon apes (Hylobates lar) contained heat-sensitive lytic activity for various mammalian oncornaviruses. Lytic activity quantitatively similar to that in gibbon serum was demonstrated in serum from three other primate species, including man; it was demonstrated to be low or absent in lower mammalian species with the exception of domestic cats, which had intermediate levels of serum lytic activity. Gibbons that acquired infectious gibbon ape leukemia virus, either naturally by exposure to a virus-shedding ape or experimentally by deliberate virus inoculation, had the same levels of serum lytic activity as did unexposed gibbons that had no detectable antibodies to gibbon ape leukemia virus. A leukemic-viremic gibbon had low or absent serum oncornavirus lytic activity. These results indicated that serum lytic activity does not necessarily protect against infection by oncornaviruses, although it may limit virus replication and/or dissemination.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 203712     DOI: 10.1093/jnci/60.3.677

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  6 in total

1.  Retrovirus sequences in a leukemic gibbon and its contact: evidence for partial provirus in the nonleukemic gibbon.

Authors:  F Wong-Staal; M S Reitz; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1979-04       Impact factor: 11.205

2.  The resistance of retroviral vectors produced from human cells to serum inactivation in vivo and in vitro is primate species dependent.

Authors:  N J DePolo; C E Harkleroad; M Bodner; A T Watt; C G Anderson; J S Greengard; K K Murthy; T W Dubensky; D J Jolly
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

3.  In vitro activation of feline complement by feline leukemia virus.

Authors:  L Kobilinsky; W D Hardy; R Ellis; S S Witkin; N K Day
Journal:  Infect Immun       Date:  1980-07       Impact factor: 3.441

4.  Evaluation of the Galalpha1-3Gal epitope as a host modification factor eliciting natural humoral immunity to enveloped viruses.

Authors:  R M Welsh; C L O'Donnell; D J Reed; R P Rother
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

5.  Complement mediates human immunodeficiency virus type 1 infection of a human T cell line in a CD4- and antibody-independent fashion.

Authors:  V Boyer; C Desgranges; M A Trabaud; E Fischer; M D Kazatchkine
Journal:  J Exp Med       Date:  1991-05-01       Impact factor: 14.307

Review 6.  Complement, viruses, and virus-infected cells.

Authors:  N R Cooper; G R Nemerow
Journal:  Springer Semin Immunopathol       Date:  1983
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.